

# ITHS Clinical Research Education Series


Innovations in Informed Consent

June 20, 2017



# Institute of Translational Health Sciences

## CLINICAL RESEARCH EDUCATION SERIES



**We love to hear from you!**

**Please connect anytime.**

**Mandy Morneault**

Manager for Regulatory Knowledge and  
Training, ITHS

**vicka@uw.edu**

**206-616-6339**

# Our Focus

- Speeding science to the clinic for the benefit of patients and communities throughout WWAMI
- We promote the translation of scientific discovery to practice by:
  - ❑ Fostering innovative research
  - ❑ Cultivating transdisciplinary research partnerships
  - ❑ Ensuring a pipeline of next-generation researchers through robust education and career development programs



Laboratory

Clinic

Community

# WORKSHOP AGENDA

**8:30-9:40**  
**Group**

**Data on Informed Consent (Seema Shah)**  
**Dissolving the Monolith of Informed Consent (Adrienne Meyer)**  
**New Directions for Informed Consent (Bran LeFae)**

**9:40-9:50**  
**Break**

**Transition to Breakout**  
• Restrooms are down the hall, to the right

**9:50-11:20**  
**Breakouts**

**Comprehension (Lyceum)**  
**Plain Language (145)**  
**UW Consent Template (238)**

**11:20-11:30**  
**Break**

**Transition to Closing Remarks**  
• Restrooms are down the hall, to the right

**11:30-11:50**  
**Group**

**Closing Remarks (Lyceum)**

# CONNECT FOUR

Meet someone from Bastyr	Meet someone who's done eConsent	Meet someone from SCCA	Meet someone who works at Fred Hutch
Meet someone from Swedish	Meet someone who works in Surgery	Meet someone who's tried Tiered Consent	Meet someone who works for ITHS
Meet someone who works in Behavioral Health	Meet someone who works in Global Health	Meet someone who works in Immunology	Meet someone who works at the VA
Meet someone from Seattle Children's	Meet someone who is a Nurse	Meet someone who is <u>not</u> a Research Coordinator	Meet someone who works in Genomics

**How to play:** Connect four dots in a row to win a small prize or fill three (or more) rows for a chance to win the grand prize! Dots can be connected horizontally, vertically or diagonally.

**PLEASE COMPLETE THE EVENT SURVEY  
AT THE CONCLUSION OF THE  
WORKSHOP.**

**THANK YOU!**

# Data on Informed Consent

**Seema K. Shah, J.D.**

Associate Professor, UW Department of Pediatrics

Faculty, Treuman Katz Center

Seattle Children's Research Institute


20 June 2017




Institute of **Translational** Health Sciences  
Accelerating Research. Improving Health.

# Case Study

You are a research coordinator obtaining consent for a randomized controlled trial of a new breast cancer treatment vs. placebo (on top of standard of care)



During consent process, one woman is impatient and doesn't want to hear all the information



When you ask why not, she says she thinks the experimental treatment will work



# Case Study

How can you tell if this potential subject understands enough to give valid informed consent?



What can you do to improve her understanding?

# Learning Objectives

## I. Where have we been?

*Review the historical, ethical and legal importance of informed consent*

## II. How are we doing?

*Discuss the data on informed consent*

## III. How can we improve?

*Data on improving consent, needs for future research on informed consent*

# I. Where have we been?

*The historical, ethical and legal importance of informed consent*



Institute of **Translational** Health Sciences  
Accelerating Research. Improving Health.

# Historical basis of informed consent

*Slater v. Baker & Stapleton (1767):*

Experimental surgery on an improperly healed broken bone

“improper  
to disunite  
the callous  
without  
consent”




Seeking  
consent was  
“the custom  
and usage of  
surgeons”

Failing to obtain consent before surgery was  
“contrary to the rule of the profession”


# Legal basis for informed consent

“Every human being of adult years and sound mind has a right to determine what will be done with his body...”


Justice Cardozo, *Schloendorff v. Society of New York Hospital*  
(1914)



# Why is informed consent important?



# Why is informed consent important?



# How important is informed consent?

A legal and ethical requirement in medicine and in (most) research with human subjects

- Requirement for medical research in 84 countries
- Can be waived in some cases

A process—not a form or an episode



1. Collaborative partnership

2. Social value

3. Scientific validity

4. Fair Subject Selection

5. Favorable risk-benefit ratio

6. Independent review

7. Informed consent

8. Respect for enrolled subjects

1. Collaborative partnership

2. Social value

3. Scientific validity

4. Fair Subject Selection

5. Favorable risk-benefit ratio

6. Independent review

**7. Informed consent**

8. Respect for enrolled subjects

# How important is informed consent?

**Widely subscribed to, but imperfectly realized!**

## II. How are we doing?

*Discuss the data on informed consent*



Institute of **Translational** Health Sciences  
Accelerating Research. Improving Health.

# Elements of informed consent

Decision-maker with capacity to consent

Disclosure of information

Understanding

Voluntariness

Consent authorization

# Data on elements of informed consent

~~Decision-maker with capacity to consent~~

Disclosure of information

Understanding

Voluntariness

~~Consent authorization~~


# Data on elements of informed consent

## Disclosure of information


Understanding

Voluntariness

# Disclosure of Information: Issues and Challenges



What  
information  
should be  
disclosed?



How should  
the  
information  
be presented?



# Disclosure of Information:

OHRP 45CFR46.116 and FDA 21CFR50.25

Disclosure-required elements

Statement of research

Purpose and procedures

Foreseeable risks and discomforts

Any benefits to subjects or others

Appropriate alternatives

Extent of confidentiality

Treatment or compensation for injury

Who to contact for answers to questions

Participation is voluntary

# Data on Disclosure

## Consent documents

- Content
- Readability and Length

## Discussion

- Content
- Quality of interaction

# Disclosure: Content of Consent Forms

Only 3/16 consent forms had all required elements

*Silverman et al. Critical Care Medicine 2001*

Most Phase I oncology consent forms (n=267) were found to include the required elements

- Purpose (92%)
- Right to withdraw (99%)
- Risk of death (67%)
- Unknown risks (84%)
- Cure as a possible benefit (5%)

*Hornig et al. NEJM 2002*

# Review of IC form content for 27 trials across 4 hospitals (abbreviated)

**Table 1.** Information Frequently Missing From PICFs

Type of Information	PICFs Missing Information (%)
Basic information	
Specific cancer being studied	12
Reason for research	12
Notice of voluntary participation	6
Options and further discussion	
Other treatment options available	12
Suggestion to discuss all options with doctor	24
Risks	
Potential for sterility	29
Irreversibility of risks	26

# Readability and Length

## Reading level is too high

*LoVerde et al, 1989, Grossman et al 1994, Paasche-Orlow et al., 2003, Sharp 2004*

- Recommendations to write form at 8<sup>th</sup> grade level
- Consent forms and templates usually written at 11<sup>th</sup> grade level or higher

## Consent forms getting longer over time

*Baker and Taub, 1983; LoVerde et al 1989; Tarnowski et al 1990; Beardsley et al 2007, Albala et al. 2010*

# Readability and Length

Reading level is too high

Consent forms getting longer over time



# Huge variation in quality of interaction



# Disclosure: Interaction

Videotaped oncologists	Survey of investigators of 12 multi-center RCTs
N=12	N=60
<ul style="list-style-type: none"><li>• 92% described study purpose &amp; reviewed treatment, tests, procedures</li><li>• 82% reviewed alternatives</li></ul>	<ul style="list-style-type: none"><li>• 58% gave full information</li><li>• 12% did not inform patients prior to randomization</li><li>• 38% did not always tell the patient about randomization</li><li>• 5% did not seek consent at all</li></ul>
<i>Albrecht et al. 1999</i>	<i>Williams &amp; Zwitter 1994</i>




# Disclosure: Interaction

## Survey of investigators (n=117) of multinational HIV trial

- 99% gave copy of IC document to read
- 97% gave opportunity to read before clinic
- 75% provided “a great deal” of information about risks & purpose
- <56% emphasized randomization
- 8.6% did formal assessment of understanding

# Summary of Data on Disclosure



# Data on elements of informed consent

Disclosure of information

**Understanding**

Voluntariness

# Overview of data on understanding

Data are limited,  
hard to compare


Data show that  
understanding is  
variable

Most subjects  
know they are in  
research


Randomization is  
poorly  
understood

Age & education  
sometimes affect  
understanding


# Understanding of research purpose



# Randomization



# Meta-analysis of data on understanding



# Variation by context?

Most variation in understanding appears to be **concept-specific**, not context-specific

**No systematic difference** in understanding across most concepts

**Randomization** especially hard to understand in U.S. and internationally

**Exception:** Right to withdraw might be less understood in developing countries

*Mandava et al. JME 2012*



# Understanding vs. appreciation

Difference between:

Comprehension of relevant information

Appreciation of how it applies

E.g., **67%** of US participants in rheumatoid arthritis trial knew some people would get a placebo

- *50% knew they may not get active drug*
- *53% knew treatment would not be decided based on symptoms*

*Criscione et al. 2003*

# Data on elements of informed consent

Disclosure of information

Understanding

**Voluntariness**

# Voluntariness

Able to  
make a  
(free)  
choice



Cartoon by C. J. Conradi. From the book THE NETWORK MARKETING GAME. © 1997 by Jon M. Taylor.

No  
coercion,  
undue  
influence



# How to measure voluntariness?

Did individuals choose *not* to participate?

Did participants feel pressure to join?


# Chose not to participate?

Study population	% who declined to participate	Cite
Cardiac intervention studies	7% (range 1-21%)	Gross et al. 2002
Breast conserving treatment trial	9%	Bijker et al. Brit J Ca 2002
Long observational study (NHANES)	18.9% for interviews, 14.7% for blood samples	NHANES
Adolescents in intensive diabetes tx study	43%	Terryak et al. Diabetes Care 1998
Guarani indians in genetics study	58%	Benitez 2002

# Felt pressure to join?

Study population	% who felt pressure	Cite
Cardiology and oncology studies in US (n=570)	2%	ACHRE 1996
Dutch parents in anticonvulsant study	25%	Van Stuijvenberg 1998
Ugandan parents in malaria tx trial	15% from others; 58% from child's illness	Pace et al. AJPH 2005

# Overview of data on voluntariness



### III. How can we do better?

*Data on improving consent, needs for future research on informed consent*



Institute of **Translational** Health Sciences  
Accelerating Research. Improving Health.



# Studies of strategies to improve consent




Data suggest extended discussion, test/feedback strategies help improve understanding



Evidence about multimedia strategies improving understanding less compelling

*Flory and Emanuel JAMA 2004; Ryan et al. Cochrane Database of Systematic Reviews 2008; Nishimura et al. BMC Med Ethics 2013; Synnot et al. Cochrane Database of Systematic Reviews 2014*

# Meta-analysis of interventions to improve understanding



# Audiovisual strategies to improve consent

“Low to very low quality evidence” that A/V interventions can improve knowledge or understanding “slightly”

Do not necessarily make a difference in terms of participation rate, willingness to participate

Not enough evidence about anxiety or satisfaction

# Data on informed consent: Remaining challenges


Hard to compare data; lack of standardized metrics or questions, sources of variation

What metrics should we use to measure understanding, voluntariness?

How to study other functions of consent?

When do people actually learn about research & make decisions?

# Data on informed consent




# Conclusions



I. Informed consent long recognized by physicians



II. Ethically important, imperfectly realized




III. Available data suggest: 1. Consent forms are long and complex 2. Understanding is variable 3. Spending more time may enhance understanding




IV. Need innovative ethics research with standardized metrics to understand how research decisions are made, can be improved

# Case Study

You are a research coordinator obtaining consent for a randomized controlled trial of a new breast cancer treatment vs. placebo (on top of standard of care)



During consent process, one woman is impatient and doesn't want to hear all the information



When you ask why not, she says she thinks the experimental treatment will work

# Case Study

How can you tell if this potential subject understands enough to give valid informed consent?



What can you do to improve her understanding?



# Acknowledgments

- Thanks to Christine Grady, Chief of the Department of Bioethics at NIH, for sharing data and slides

# Dissolving the monolith of informed consent



Adrienne Meyer, MPA  
Assistant Director, UW Human Subjects Division

**ITHS** | Institute of Translational Health Sciences  
Accelerating Research. Improving Health.





# The first crack in the monolith

## In order to approve research:

- An IRB shall require that **information given to subjects** as part of informed consent is **in accordance with §46.116.**
- An IRB shall require **documentation of informed consent** or **may waive** documentation **in accordance with §46.117.**

# What does this mean?

Informed consent is conceived of in the Common Rule as primarily in relation to the information given to subjects

When a written consent form is referred to, it is primarily referred to as a way to document consent



# Another little crack

The consent form may be either of the following:

- A **written consent** document that embodies the **elements** of informed consent **required by §46.116**.
- A **short form** written consent document stating that the **elements** of informed consent **required by §46.116** have been **presented orally** to the subject or the subject's legally authorized representative.



# What does this mean?

There are already two types of written consent forms described in the regulations

There is no definition in the regulations for  
“written consent form”

# One more tap of the hammer



An IRB may waive the requirement for the investigator to obtain a signed consent form for some or all subjects if it finds either:

- That the only record linking the subject and the research would be the consent document and the **principal risk** would be potential harm resulting from a **breach of confidentiality**.
- That the research presents no more than **minimal risk of harm** to subjects and involves **no procedures** for which written consent is **normally required** outside of the research context.



# What does this mean?



For minimal risk research, written documentation of consent can almost always be waived

For some research greater than minimal risk, written consent can also be waived.

# Let's open up another crack

An IRB may approve a consent procedure which does not include (or which alters) some or all of the elements of informed consent...  
...or waive the requirement to obtain informed consent provided the IRB finds and documents that:

- The research involves no more than minimal risk to the subjects;
- The waiver or alteration will not adversely affect the rights and welfare of the subjects;
- The research could not practicably be carried out without the waiver or alteration; and
- Whenever appropriate, the subjects will be provided with additional pertinent information after participation.

# What does this mean?

## FOR MINIMAL RISK RESEARCH:

If the research cannot practicably be carried out under the requirements for obtaining consent, the IRB can:

Waive the need to obtain consent at all

Waive the need for subjects to be provided with certain pieces of information


# What about the FDA?

**YES!**

Waiver of written  
documentation for  
**minimal risk** research

**NO**

General waiver of  
consent or elements



**YES!**

Waiver of  
consent for  
**emergency  
medicine**  
research



# The IRB may even give you a hammer

3.2 UW Consent Form Templates. Though it is not an absolute requirement, researchers are encouraged to use one of the UW consent templates when drafting a consent form. Use of the templates ensures compliance with federal and state regulatory requirements as well as UW-specific issues. However, the UW IRB recognizes that there are some circumstances where a significantly different form, organization, and/or approach may be more appropriate.

...and a chisel



3.7.3 “Researcher” signature. The person who obtained consent from the subject must also sign and date the consent form if the research involves more than minimal risk to subjects. The signature cannot pre-date the subject’s signature. The purpose of the signature is to document that the person has explained the research to the subject and answered the subject’s questions.



### Host Immune Responses to Microbial Pathogens

#### 4) What will happen during this study and how long will it last?

However, some patients with specific infections may be asked to have additional blood samples collected to look for changes in the immune response.

These samples may be collected during your regularly scheduled follow-up visits related to your infection or you may be requested to return specifically to have these samples collected for research purposes only.

If you have already had a blood draw as standard of care, we may be able to use this instead of having to repeat it.

If you are on a machine to help you breathe, a mucous sample may be collected from the tube that is helping you breathe. Some patients will have pleura fluid that is in the chest removed as part of their routine care. If this is done, we will use part of this fluid to perform laboratory tests. This sample will only be collected if it is done as part of your routine care. It will not be obtained for research purposes only.

**Respiratory Samples**

We may also collect a mucous sample. Depending on the type of infection you have, the following samples may be collected to look for mucosins and to look at the body's responses to infections.

- Nasal wash - done by squirting about half a teaspoon of salt water into your nose and sucking it back out quickly.
- Nasal flush - done by rubbing the inside of the nose with a cotton swab.
- Throat swab - done by rubbing the back of the throat with a small cotton ball at the end of a stick.

Try A Nasal Swab

If you have already had a blood draw as standard of care, we may be able to use this instead of having to repeat it. These samples will generally be collected 1 time.

Previous Next

Screen 11 of 26

### THE PRIDE STUDY

Network consent and data processing information

If you consent to being interviewed and to have your network being processed as part of the study, please give your name, any phone numbers, any email addresses

- The Project, "PROJECT PRIDE", is being conducted by research teams at the Public Health University. It is funded by the Government of Ontario Research Council (GRF), 111
- All data will be treated as personal under the 1993 Data Protection Act, and will be processed lawfully.
- Interviews are recorded for the researchers and transferred to all participating teams to be used for research purposes.
- Consent to participate in this research will be obtained from the GRF Data Protection Officer.
- Activities of this research project will be limited to: free of charge, on-line; data will not be processed manually and with the aid of computer software.
- Researcher(s) will be using CRM of the Open Office, whether you are willing to participate or not. We may send you work items in response and participate in any form of the research.
- This research project is not supported by any identified or unidentifiable records and will be used for research purposes and the GRF Data Protection Officer.
- Network(s) for my employer may be identified to inform them, especially for the network(s) and the GRF Data Protection Officer.
- Network(s) for my employer may be identified to inform them, especially for the network(s) and the GRF Data Protection Officer.
- Network(s) for my employer may be identified to inform them, especially for the network(s) and the GRF Data Protection Officer.

Participant's name: \_\_\_\_\_  
Signature: \_\_\_\_\_ Date: \_\_\_\_\_



## Project PrEPare: FAQ's

**What is Project PrEPare?**  
Project PrEPare is a research study for young guys and trans girls. The project focuses on PrEP:

- safety
- efficacy
- use patterns
- adherence rates
- and sexual risk patterns

to determine if PrEP could be part of a HIV prevention package for young guys and trans girls.

**What sexual health services will eligible Project PrEPare participants receive?**

Eligible participants receive:

- Physical exams
- HIV/STI testing & treatment
- Sexual health counseling
- PrEP, condoms & lube
- Compensation for time & transportation

## rethinking HIV prevention

Where will Project PrEPare take place?  
Project PrEPare is taking place in 12 cities across the United States, including Baltimore, Boston, Chicago, Denver, Detroit, Houston, Los Angeles, Memphis, Miami, New Orleans, Philadelphia, and Tampa.

When will Project PrEPare begin, and how long will it last?  
Project PrEPare began in the fall of 2012, and is still open to participation by 15, 16 & 17 year olds in the Chicago-Land area. Participants attend 9 visits in 12 months time.

Who sponsors Project PrEPare?  
Project PrEPare is a study of the Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) and is funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the National Institute on Drug Abuse (NIDA) and the National Institute of Mental Health (NIMH). Gilead Sciences donates Truvada for Project PrEPare.

Contact Information:  
Pedro Alonso Serrano  
(708) 683-9415  
pedroalonsoserrano@gmail.com

CORE Center, 2nd FLR West  
2020 W. Harrison  
Chicago, IL 60612  
projectprep.net

### Informed Consent Process


- ✓ oral presentation
- ✓ additional materials
- ✓ video presentation

### Survivor Mama, teaching consent

Survivor Mama, a teaching tool for teaching consent, is a comic book that teaches young women about consent and how to say no.

Survivor Mama, a teaching tool for teaching consent, is a comic book that teaches young women about consent and how to say no.

Survivor Mama, a teaching tool for teaching consent, is a comic book that teaches young women about consent and how to say no.



# Carve something great



# New Directions for Informed Consent



Bran LeFae  
Medical Writer, Seattle Genetics

**ITHS** | Institute of Translational Health Sciences  
Accelerating Research. Improving Health.


*All opinions expressed in the course of this presentation are mine alone. This presentation does not include any information about current Seattle Genetics practices.*



# What is Informed Consent?

“...a process of providing potential participants with relevant information that they understand and use to make informed and voluntary decisions...”<sup>1</sup>

# Traditional Paper Consent – Challenges and Limitations



# Emerging Models of Informed Consent

eConsent<sup>2</sup>

Tiered  
consenting<sup>3,4</sup>

Staged  
consenting<sup>5</sup>

Tools for  
enhanced  
consenting

Visual aids<sup>6</sup>  
Plain language

# eConsent

Plenty of interest at the sponsor level and at sites



IRBs are starting to review studies using eConsent



Early days – so far, only used by a small number of studies

In December 2016, FDA issued “Use of Electronic Informed Consent, Questions and Answers. Guidance for Institutional Review Boards, Investigators, and Sponsors.”


- Essentially who, what, when, where, and how
- Electronic signatures
- Confidentiality
- IRB review (materials needed, etc.)

# eConsent

Pros	Cons
<p>Hotlinks can give participants the ability to get a word defined, learn more about a phrase, or access visual, video, or live chat options.</p>	<p>Not all participants find electronic consent inviting. Some populations have a strong preference for paper documents over electronic.</p>
<p>Easy to set up for a tiered or staged consenting approach.</p>	<p>Potentially decreased interaction with the study team and physician or investigator.</p>
<p>Can be used to consent remotely for certain studies.</p>	<p>Still have to give a paper copy to participants.</p>

# Tiered Consent

Emerging model that allows the potential participant to guide the level of detail for any given item while still meeting all required elements of consent.



# Tiered Consent

## Pros

May pair well with an electronic platform, allowing the participant to dig into more detail through hotlinks, video, and diagrams.

This model can serve as a way to get broad consent for an overarching study (ex: genetic analysis) with the participant offering further consent for each specific test.

Participants who are consenting for a complicated or frightening study can control how much detail they receive in the consenting discussion.

Participants can give continued informed consent by agreeing to take part in the greater study and consenting at each visit to the tests and procedures.

## Cons

As a new model, there is no data to tell us if this informs participants more or less than a traditional full consent approach

# Staged Consenting

Model often used in pediatric oncology studies, where patients start with a standard of care treatment. During treatment, parents and physicians have a series of consenting discussions to explore the clinical trial.

## Pros

Parents have a longer period to consider the clinical trial, more chances to ask questions, and time to weigh the risks and benefits.

## Cons

The study design has to allow for a longer consenting period. This is not a one size fits all consenting model.



# Visual Aids

The eye and brain react to the visual display of communication as well as the content.

Graphics can be used to increase understanding of a concept and to bridge health literacy gaps in communication.

Visual tools must be created with the audience in mind.

Engaging the audience for feedback is often essential, given the inherent limitations of understanding how other people interpret visual information.

Many people are challenged in understanding and working with numbers. Graphics can help bridge this gap.

# Plain Language

Are we meeting that standard?

Regulations and best practices require us to use language that is “...as non-technical as practical and should be understandable to the subject...” (Good Clinical Practice) and write consents “...in language understandable to the subject...” (Common Rule 45 CFR 46.111).

Health literacy research data created communication standards, eventually packaged as “plain language”.



Plain language techniques use simple tools to create clear, engaging communication.



Regardless of consent model or platform, plain language helps you reach your patient or participant by bridging any health literacy gaps.

Questions?